About

Dr. Raymond (Ray) Hill was previously a member of Addex's Board of Directors from the Annual General Meetings of 2008 until 2012. He is Visiting Professor of Pharmacology at Imperial College London, Chairman/Non-Executive Director of Avilex (Denmark) and a member of the Scientific Advisory Board of Neurosterix. He was previously Chair of the SAB of Asceneuron (2014-2021) and a Non-Executive Director of Orexo AB (2008-2019). Before retirement he was Executive Director, Licensing and External Research at Merck/MSD in Europe (2002-2008) and Executive Director, Pharmacology (1990-2002) at the Merck Neuroscience Research Centre, with oversight of neuroscience research at the Banyu Research Labs in Japan. He is President Emeritus of the British Pharmacological Society and a Fellow of the Academy of Medical Sciences. He received his academic training (BPharm, PhD) at the University of London and an Honorary DSc from the University of Bradford.

Roles

Addex Therapeutics Ltd.
Director · Current role
Present
Merck/MSD Europe
Executive Director, Licensing and External Research
2002 - 2008
Merck Neuroscience Research Centre
Executive Director, Pharmacology
1990 - 2002
Orexo AB
Non-Executive Director
2008 - 2019
Asceneuron
Chair, Scientific Advisory Board
2014 - 2021

External Roles

Imperial College London
Visiting Professor of Pharmacology
present
Avilex (Denmark)
Chairman / Non-Executive Director
present
Neurosterix
Scientific Advisory Board member
present
University of Bristol
Visiting Professor
present

Director Compensation

FY 2025
Fixed compensation
CHF 18,017
ComponentFixed annual Board compensation, FY2025 (CHF)
Variable cash (attendance)
CHF 18,017
ComponentVariable cash based on Board-meeting attendance, FY2025
Total
CHF 36,034
BasisNo equity incentive units were granted to Board members in 2025.

Also at Addex Therapeutics Ltd.

Related

See how VectorShift works for your firm

Request Demo